and a preserved host immune system. Data on the effect of HLA mismatching on the incidence of graft failure showed We examined five children who underwent allogeneic an overall increase in the incidence in the mismatched peripheral stem cell transplantation (PSCT) using posigroup compared to HLA-identical sibling bone marrow tively selected CD34 ؉ cells from three or two loci-mistransplantation (BMT) and the frequency of graft failure matched donors. CD34
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؉ cells mobilized from peripheral increased as donor/recipient HLA disparity increased. 3, 4 blood were separated by immunomagnetic beads. While the host immune system is defeated by T cells con-CD34 ؉ cells at 2.2-6.2 ؋ 10 6 /kg were transplanted into tained in the grafts, in the case of SCT with T cell-depleted three patients with refractory leukemia, a patient with grafts, immune competent cells in recipients are preserved. relapsed medulloblastoma and a patient with Fanconi's In the mouse model, the immunologic rejection of T cellanemia following a conditioning regimen which depleted histoincompatible BMT can be overcome by included irradiation, alkylating agents and antithymoincreasing the doses of irradiation or by adding selective cyte globulin treatment. The number of infused CD3 ؉ measures with minimal toxicity, such as splenic irradiation cells included in grafts was 2.3-22.7 ؋ 10 4 /kg. Four or in vivo treatment with anti-T cell monoclonal antibodies, patients achieved engraftment and hematopoietic reconto the conditioning regimen. [5] [6] [7] However, previous results stitution (Ͼ5 ؋ 10 8 /l of neutrophils on day 10 or 11).
of clinical trials using these procedures have not been satisGraft rejection was observed in the patient with Fanfactory. 8, 9 Another means of overcoming graft failure is to coni's anemia, but a rapid engraftment was obtained increase the number of stem cells in the graft. This has been after second PSCT. Although no prophylactic agents found to be the case in studies investigating the relationship other than ATG (included in the conditioning regimen) between transfused cell doses and the incidence of rejecwere used, greater than grade I acute GVHD was not tion. 10 Recently, successful engraftment using positively observed, but limited chronic GVHD was observed in selected allogeneic CD34 + bone marrow cells from two or two patients. The two patients with leukemia relapsed three loci-mismatched donors was reported. This procedure on days 103 and 210, respectively, and the patient with enables a larger number of transplantable stem cells. 11, 12 medulloblastoma died of disease on day 159. The patient The administration of recombinant human granulocyte with Fanconi's anemia died of fungal infection. CMV colony-stimulating factor (rhG-CSF) can mobilize a sufand HHV-6 diseases developed in four and two patients, ficient number of peripheral stem cells (PSCs) to permit respectively. Thus, although SCT using positively selecthe collection of a transplant inoculum. Infusion of these ted peripheral CD34 ؉ cells may be an alternative cytokine-mobilized cells resulted in rapid engraftment of approach for overcoming graft rejection and GVHD hematopoietic cells, sustained hematopoiesis and immune from HLA-mismatched donors, persistent immune reconstitution in autologous transplant. [13] [14] [15] Allogeneic PSC deficiency attributing to extremely low numbers of T transplantation (PSCT) has also been reported and can cells in grafts can potentially lead to reactivation of herprovide long-term multilineage hematopoiesis. 13 T cellpes viruses.
depleted PSCT (negative selection) from mismatched Keywords: CD34 + cells; allogeneic PSCT; positive donors was shown to overcome graft failure because of an selection; mismatched donor increased number of stem cells in the grafts. Therefore, in this study, we attempted HLA-mismatched allogeneic PSCT to five children with positively selected CD34 + hemAlthough transplantation with T cell-depleted bone marrow atopoietic cells using immunomagnetic beads to overcome cells from haploidentical donors is an alternative approach graft failure and reduce the severity of GVHD. We for patients without HLA-matched donors, this treatment is designed a conditioning regimen that included antithymoat high risk for graft failure. 1, 2 The causes of graft failure cyte globulin (ATG) for the enhancement of immunoin such stem cell transplantation (SCT) are HLA disparity suppression and the prophylaxis of GVHD. As a result, engraftment and sustained hematopoiesis were obtained in five of six transplants, and despite the use of no prophylac- The cells were frozen at Ϫ80°C until use. leukemia (AML, M2) at refractory relapse after syngeneic BMT. The interval between the relapse and BMT was 8 months. The other two with acute leukemia had B cell preConditioning regimen (Table 2 ) cursor acute lymphoblastic leukemia (ALL) at second
The conditioning regimen for leukemia (patients 1-3) conrelapse and T cell ALL at second complete remission. + cells sive therapy other than ATG was administered for GVHD prophylaxis. Leukapheresis products were passed over a nylon wool fiber to remove monocytes; this procedure allowed for high recovery rates of CD34 + cells. 16 Cells expressing the CD34 Supportive treatment antigen were enriched from leukapheresis products using the Baxter Isolex system (Immunotherapy Division, Baxter All patients were treated under laminar air-flow and received prophylactic antibiotics and amphotericin-B for Healthcare, Irvine, CA, USA) according to the manufac- (Table 3) neutrophil count to 1.0 × 10 9 /l was observed on day 20, the number of neutrophils decreased gradually and the rejection Adverse effects associated with the injection of G-CSF included bone pain, myalgia and general fatigue, but were of the graft was confirmed by VNTR analysis. The second transplant was performed from the same donor 41 days mild and improved in all subjects by administration of acetaminophen. After G-CSF treatment, one to three leukapherafter the first one. Engraftment was rapid, and neutrophil counts of greater than 0.5 × 10 9 /l were achieved on day 12. eses yielded 1.5-18.9 × 10 8 /kg mononuclear cells and leukapheresis products contained 0.14-0.90% of CD34 + Lymphocyte subsets after transplantation were analyzed in patients 1 to 4 (Figures 1 and 2 cal course in all cases. The proportion and absolute number of CD3 + T cells in patients 1-3 were markedly lower than PSCT in patients 1 and 4, it gradually decreased during the after PSCT with unmanipulated grafts, even after T cellclinical course. In other patients, the number of CD8 + cells depleted BMT, 20 and did not reach the normal level in was low. patients 1 and 2 with leukemia up to 210 days after transplantation. In patient 4 with medulloblastoma, the proportion of CD3 lymphocytes steadily increased and reached GVHD the normal level 1 month after PSCT. However, after CMV infection, CD3
+ cells decreased below 10%. The number Patients 1 and 3 showed no acute GVHD. Patients 2, 4 and 5 developed grade I acute GVHD of the skin on day 24, of CD4 + lymphocytes in all cases was extremely low during the clinical course. The number of CD4 + cells did not 12 and 40, respectively. These patients rapidly responded to treatment with glucocorticoid. Chronic GVHD limited to exceed 0.1 × 10 9 /l by day 90. Although the number of CD8 + cells was normal or above normal within 3-4 months after the skin was observed in patients 3 and 4.
Toxicity and clinical outcome the TBI dose was able to be reduced to 3 Gy using ATG, busulfan and thiotepa in patient 4 with a non-hematological Viral infection was the most serious complication in malignancy. Despite the intensive conditioning regimen patients 2-5. CMV retinitis occurred in patients 2 and 4 on used in this study, infection associated with BM aplasia did days 120 and 60, respectively, without evidence of CMV not develop in these cases due to rapid BM reconstitution disease in other sites but was resolved with administration (Ͼ5 × 10 8 /l neutrophils on days 10-12). In the PSCT from of GCV at 10 mg/kg. In patient 4, after stopping GCV HLA-matched donors, engraftment was faster than in the administration, CMV infection recurred in the lung leading BMT for both granulocytes and platelets. 23 According to a to interstitial pneumonitis on day 120. Despite prophylactic recent study of three patients who received HLA-misadministration of ACV, patient 3 developed varicella on matched SCT with positively selected CD34 + cells from day 35 after transplantation. Since dose escalation of ACV BM, it took 11, 13 and 16 days, respectively, to reach was ineffective, GCV was administered, but the effect was Ͼ5 × 10 preventive therapy for GVHD after transplantation except A relapse in the bone marrow was detected in patient 1 for patient 5, who received ATG again after the second on day 103 after transplantation and he was treated with a transplantation for the prevention of the graft rejection, transfusion of donor lymphocytes (1 × 10 8 /kg). Grade III acute GVHD documented was mild and transient (grade I in acute GVHD occurred, and he was treated with methylpredthese patients). Immune reconstitution is another concern. nisolone. Despite no evidence of leukemia, GVHD induced Because of the extremely low number of T cells transmarrow aplasia, and the patient died of pneumonia on day planted, an increase in T cell number was delayed in these 159 post transplant. Patient 2 had once achieved complete cases. Although no or slight GVHD was observed and remission but relapsed on day 210 and died of leukemia on prophylactic GCV was given, CMV and HHV-6 diseases day 267. Patient 4 showed partial response but the tumor occurred in three and two cases, respectively. It is possible regrew and he died on day 159. Patient 3 maintains that the administration of ATG included in the preparative complete remission.
regimen for the prevention of graft rejection and GVHD may have delayed T cell reconstitution and promoted reactivation of CMV and HHV-6.
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Discussion
Based on previous studies by others, it is clear that SCT with T cell-depleted BM yields relapse of leukemia in high frequencies due to the decrease of the GVL effect. 21 Thus, Allogeneic SCT is usually the only procedure offering a cure to children with refractory hematological malig-SCT with positively selected CD34 + cells contaminated with an extremely low number of T cells may increase the nancies. However, appropriate donors are only available for a limited number of patients. For recipients without approfrequency of recurrence of leukemia. However, in the case of HLA-mismatched SCT using in vivo and in vitro purging priate donors, HLA-haploidentical relatives are used as alternative donors. Depletion of T cells from grafts using with Campath 1, no increase in the relapse rate was observed. 26 This may be explained by the GVL effect negative selection has been performed for SCT from HLAmismatched donors. Such a procedure increases the freenhanced by the disparity of HLA. Four of five patients in our study exhibited acute and/or chronic GVHD. Therefore, quency of graft failure and relapse of leukemia. 1, 2, 21 In our study, the number of CD34 + cells in grafts obtained by it is plausible that SCT with positively selected CD34 + cells from HLA-mismatched donors does not increase the relapse positive selection from mobilized PSCs was two-to threefold that in grafts negatively selected. As a result of rate compared to conventional SCT from matched siblings. Indeed, patient 2, who had been refractory to anti-leukemia infusion of a larger number of hematopoietic cells, engraftment was easily achieved and no graft rejection was therapies and had a large tumor burden before SCT, maintained complete remission for 7 months after SCT, and observed in four of five patients. Indeed, a 7-to 10-fold increase in the dose of the T cell-depleted hematopoietic patient 4 maintained complete remission for 4 months. Thus, although no conclusions on the clinical outcome cells sustained stable engraftments in SCT from haploidentical HLA-mismatched donors. 22 Although an intensive concan be drawn in this small series of patients, our results suggest that SCT with enriched CD34 + cells positively ditioning regimen consisting of TBI, ATG, thiotepa, and cyclophosphamide or L-PAM was applied in patients 1-3, selected from mobilized PSCs may become a useful pro- 
